Cut Through a Crowded TCE Market
How do you identify the most promising targets in a crowded landscape? Which programs are emerging as future market leaders? Where are competitors, and investors placing their bets? How is the shift into solid tumors reshaping the next generation of TCE innovation?
Drawing on data from Beacon Bispecific, this report analyzes the assets, clinical trials, target combinations, companies, and deals shaping the TCE market in 2026, helping you answer these tough questions.
Download the report to discover:
- How the TCE landscape has grown to 1,155 assets, and what this means for competitive differentiation.
- Which targets and target combinations are attracting attention, including emerging PSMA- and STEAP1-focused programs.
- Which assets are progressing towards late-stage development and potential approval.
- Where investment and partnering activity is flowing, including multiple billion-dollar licensing deals.
- How competition is evolving through next-generation formats, trispecific TCEs, and growing development activity in China.
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
